文章基本信息

标题：Use of Sample Hematocrit Value to Correct Blood Tacrolimus Concentration Derived by Microparticle Enzyme Immunoassay
本地全文：下载
作者：Takashi Tomita ; Masato Homma ; Yuichi Hasegawa 等
期刊名称：Biological and Pharmaceutical Bulletin
印刷版ISSN：0918-6158
电子版ISSN：1347-5215
出版年度：2008
卷号：31
期号：6
页码：1250-1253
DOI：10.1248/bpb.31.1250
出版社：The Pharmaceutical Society of Japan
摘要：The quality of microparticle enzyme immunoassay (MEIA) for blood tacrolimus is guaranteed in samples with hematocrit (Ht) values of 25 to 45%. Because MEIA provides inaccurate blood tacrolimus concentrations in samples with Ht out of this range ( i.e. <25% or >45%), correction of the calibration is required for therapeutic drug monitoring. The authors demonstrated previously that overestimated MEIA tacrolimus concentration could be corrected by modified, calibrated MEIA (cMEIA) using the original calibrator. Here, an equation was established to more easily derive a corrected tacrolimus concentration by calculation (MEIAcalc) using the Ht of each sample. The tacrolimus concentrations of 99 whole-blood samples with low Ht (<25%) were then tested by the 3 assay methods: MEIA, cMEIA, and MEIAcalc. MEIA gave a significantly higher blood concentration of tacrolimus (median 12.9 ng/ml, range 3.6—26.4 ng/ml) than did cMEIA (median 10.0 ng/ml, range 0.2—21.1 ng/ml, p <0.05). This overestimation was eliminated by using MEIAcalc. There was no difference in blood tacrolimus concentration between cMEIA and MEIAcalc (median 10.0 ng/ml, range 1.7—21.4 ng/ml). MEIAcalc can be used to correct the tacrolimus concentration in samples obtained from patients with unstable Ht values.
关键词：tacrolimus;hematocrit value;overestimation;microparticle enzyme immunoassay;therapeutic drug monitoring